Department of Medicine, Division of Digestive and Liver Diseases, New York Presbyterian Columbia University Medical Center, New York, NY, USA.
Department of Biomedical Informatics, New York Presbyterian Columbia University Medical Center, New York, NY, USA.
Neurogastroenterol Motil. 2022 Mar;34(3):e14251. doi: 10.1111/nmo.14251. Epub 2021 Sep 1.
BACKGROUND: COVID-19 frequently presents with acute gastrointestinal (GI) symptoms, but it is unclear how common these symptoms are after recovery. The purpose of this study was to estimate the prevalence and characteristics of GI symptoms after COVID-19. METHODS: The medical records of patients hospitalized with COVID-19 between March 1 and June 30, 2020, were reviewed for the presence of GI symptoms at primary care follow-up 1 to 6 months later. The prevalence of new GI symptoms was estimated, and risk factors were assessed. Additionally, an anonymous survey was used to determine the prevalence of new GI symptoms among online support groups for COVID-19 survivors. KEY RESULTS: Among 147 patients without pre-existing GI conditions, the most common GI symptoms at the time of hospitalization for COVID-19 were diarrhea (23%), nausea/vomiting (21%), and abdominal pain (6.1%), and at a median follow-up time of 106 days, the most common GI symptoms were abdominal pain (7.5%), constipation (6.8%), diarrhea (4.1%), and vomiting (4.1%), with 16% reporting at least one GI symptom at follow-up (95% confidence interval 11 to 23%). Among 285 respondents to an online survey for self-identified COVID-19 survivors without pre-existing GI symptoms, 113 (40%) reported new GI symptoms after COVID-19 (95% CI 33.9 to 45.6%). CONCLUSION AND INFERENCES: At a median of 106 days after discharge following hospitalization for COVID-19, 16% of unselected patients reported new GI symptoms at follow-up. 40% of patients from COVID survivor groups reported new GI symptoms. The ongoing GI effects of COVID-19 after recovery require further study.
背景:COVID-19 常伴有急性胃肠道(GI)症状,但目前尚不清楚这些症状在康复后有多常见。本研究旨在评估 COVID-19 后胃肠道症状的患病率和特征。
方法:对 2020 年 3 月 1 日至 6 月 30 日期间因 COVID-19 住院的患者的病历进行回顾性分析,以了解他们在 1 至 6 个月后的初级保健随访中是否出现新的胃肠道症状。估计新胃肠道症状的患病率,并评估危险因素。此外,还使用匿名调查来确定 COVID-19 幸存者在线支持小组中新胃肠道症状的患病率。
主要结果:在 147 名无预先存在的胃肠道疾病的患者中,COVID-19 住院期间最常见的胃肠道症状为腹泻(23%)、恶心/呕吐(21%)和腹痛(6.1%),在中位数为 106 天的随访期间,最常见的胃肠道症状为腹痛(7.5%)、便秘(6.8%)、腹泻(4.1%)和呕吐(4.1%),16%的患者在随访时至少报告有一种胃肠道症状(95%置信区间为 11 至 23%)。在一项针对无预先存在的胃肠道症状的自我认定 COVID-19 幸存者的在线调查中,285 名受访者中有 113 名(40%)报告 COVID-19 后出现新的胃肠道症状(95%CI 33.9 至 45.6%)。
结论和推断:在 COVID-19 住院后中位数为 106 天的随访中,16%的未选择患者在随访时报告出现新的胃肠道症状。40%的 COVID 幸存者群体报告出现新的胃肠道症状。COVID-19 康复后持续存在的胃肠道影响需要进一步研究。
Neurogastroenterol Motil. 2022-3
Clin Gastroenterol Hepatol. 2024-5
J Clin Gastroenterol. 2021-1
Scand J Gastroenterol. 2023
J Cell Immunol. 2024
Indian J Gastroenterol. 2024-6
Am J Gastroenterol. 2021-1-1
Clin Microbiol Infect. 2021-2
JAMA. 2020-10-13
Clin Microbiol Infect. 2020-11
Clin Gastroenterol Hepatol. 2021-9
JAMA. 2020-8-11